N -Acetylcysteine Does Not Influence the Activity of Endothelium-Derived Relaxing Factor In Vivo
- 1 February 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 29 (2) , 668-672
- https://doi.org/10.1161/01.hyp.29.2.668
Abstract
Nitric oxide forms complexes with an array of biomolecular carriers that retain biological activity. This reactivity of nitric oxide in physiological systems has led to some dispute as to whether endothelium-derived relaxing factor is nitric oxide or a closely related adduct thereof, such as a nitrosothiol. In vitro bioassays used to address this question are limited by the exclusion of biological thiols that are requisite for nitrosothiol formation. Thus, the purpose of this study was to obtain insight into the identity of endothelium-derived relaxing factor in vivo. We reasoned that if endothelium-derived relaxing factor is nitric oxide, infusion of physiological concentrations of thiol would potentiate its bioactivity by analogy with effects seen in vitro, whereas nitrosothiol would be resistant to such modulation. We used venous-occlusion plethysmography to study forearm blood flow in normal subjects. Methacholine (0.3 to 10 μg/min) and nitroglycerin (1 to 30 μg/min) were infused via the brachial artery to elicit endothelium-dependent and endothelium-independent vasodilation, respectively. Dose-response determinations were made for each drug before and after an intra-arterial infusion of the reduced thiol, N -acetylcysteine, at rates estimated to achieve a physiological concentration of 1 mmol/L. Methacholine increased forearm blood flow in a dose-dependent manner. Infusion of N -acetylcysteine did not change the sensitivity (ED 50 , 1.7 versus 1.7 μg/min, P =NS) or maximal response to methacholine. In contrast, thiol increased the sensitivity to nitroglycerin (ED 50 , 4.7 versus 2.8 μg/min, P <.01). Thus, conflicting with reports in vitro, thiol does not modulate endothelium-derived relaxing factor responses in vivo. These data indicate that sulfhydryl groups are not a limiting factor for endothelium-derived relaxing factor responses in forearm resistance vessels in normal humans and are in keeping with reports that nitrosothiol contributes to endothelium-derived relaxing factor bioactivity in plasma and vascular smooth muscle. Potentiation of the effects of nitroglycerin by N -acetylcysteine can be attributed to its enhanced biotransformation to an endothelium-derived relaxing factor equivalent, such as nitrosothiol. These observations support the notion of an equilibrium between nitric oxide and nitrosothiol in biological systems that may be influenced by redox state.Keywords
This publication has 21 references indexed in Scilit:
- Understanding the controversy over the identity of EDRFNature, 1994
- A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compoundsNature, 1993
- Biochemistry of Nitric Oxide and Its Redox-Activated FormsScience, 1992
- Accelerating Action of Quinidine on the Decay Phase of Transient Outward Current in Dissociated Hippocampal Pyramidal Neurons of Rats.The Japanese Journal of Pharmacology, 1992
- The antithrombotic effects of organic nitratesTrends in Cardiovascular Medicine, 1991
- Endothelium‐derived relaxing factor is a nitrosyl iron complex with thiol ligandsFEBS Letters, 1991
- H2O2 and endothelium-dependent cerebral arteriolar dilation. Implications for the identity of endothelium-derived relaxing factor generated by acetylcholine.Hypertension, 1990
- Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.Journal of Clinical Investigation, 1990
- Endothelium-derived relaxing factorPharmacology & Therapeutics, 1989
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987